AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?
AstraZeneca has entered into a $1.5 billion deal to secure global rights to Zegfrovy, a targeted therapy for non-small cell lung cancer. The pharmaceutical giant will pay $600 million upfront and could receive an additional $900 million if Zegfrovy meets certain milestones. Dizal Pharmaceutical, the maker of Zegfrovy, will also receive tiered royalties on global sales.
Zegfrovy is approved in the US and China for patients with specific EGFR mutations who have progressed after platinum-based chemotherapy. AstraZeneca will be responsible for the drug's development and commercialization. This acquisition bolsters AstraZeneca's oncology portfolio, which already includes Tagrisso, Imfinzi, and Enhertu.
The product's approval in the US and China represents a significant milestone, and the company's global regulatory and commercial capabilities may extend its reach further. However, the deal's value hinges on Zegfrovy's ability to gain broader adoption beyond its targeted patient population and generate substantial revenue.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
